Literature DB >> 25758829

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Craig S Sauter1, Matthew J Matasar1, Jessica Meikle2, Heiko Schoder3, Gary A Ulaner3, Jocelyn C Migliacci2, Patrick Hilden4, Sean M Devlin4, Andrew D Zelenetz1, Craig H Moskowitz1.   

Abstract

High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using (18)F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients achieving a Deauville response of 1 to 3 to ST experienced superior progression-free survival (PFS) and overall survival (OS) rates of 77% and 86%, respectively, compared with patients achieving Deauville 4 (49% and 54%, respectively) (P < .001). No other pre-HDT-ASCT risk factors significantly impacted PFS or OS. Despite achieving remission to ST, patients with Deauville 4 should be the focus of risk-adapted investigational therapies.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25758829      PMCID： PMC4624450          DOI： 10.1182/blood-2014-10-606939

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.

Authors:  Michael Dickinson; Rosemary Hoyt; Andrew W Roberts; Andrew Grigg; John F Seymour; H Miles Prince; Jeff Szer; David Ritchie
Journal:  Br J Haematol       Date:  2010-05-07       Impact factor: 6.998

2.  Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Enrico Derenzini; Gerardo Musuraca; Stefano Fanti; Vittorio Stefoni; Monica Tani; Lapo Alinari; Filippo Venturini; Letizia Gandolfi; Michele Baccarani; Pier Luigi Zinzani
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

3.  Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.

Authors:  V Roland; C Bodet-Milin; A Moreau; T Gastinne; B Mahé; V Dubruille; H Maisonneuve; N Juge-Morineau; P Moreau; H Jardel; L Planche; M Mohty; P Moreau; J-L Harousseau; F Kraeber-Bodéré; S Le Gouill
Journal:  Bone Marrow Transplant       Date:  2010-05-31       Impact factor: 5.483

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

Review 5.  Interim PET-CT in the management of diffuse large B-cell lymphoma.

Authors:  Craig H Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

6.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Authors:  Christian Gisselbrecht; Norbert Schmitz; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Noel J Milpied; John Radford; Nicolas Ketterer; Ofer Shpilberg; Ulrich Dührsen; Hans Hagberg; David D Ma; Andreas Viardot; Ray Lowenthal; Josette Brière; Gilles Salles; Craig H Moskowitz; Bertram Glass
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

Authors:  Bradford S Hoppe; Craig H Moskowitz; Daniel A Filippa; Chaya S Moskowitz; Tarun Kewalramani; Andrew D Zelenetz; Andrew D Zelenet; Joachim Yahalom
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

9.  The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.

Authors:  B S Hoppe; C H Moskowitz; Z Zhang; J C Maragulia; R D Rice; A S Reiner; P A Hamlin; A D Zelenetz; J Yahalom
Journal:  Bone Marrow Transplant       Date:  2009-01-12       Impact factor: 5.483

10.  Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

Authors:  Michel Meignan; Andrea Gallamini; Michel Meignan; Andrea Gallamini; Corinne Haioun
Journal:  Leuk Lymphoma       Date:  2009-08
View more
  30 in total

Review 1.  Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

Authors:  Miguel-Angel Perales; Craig S Sauter; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-17       Impact factor: 5.742

2.  Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL.

Authors:  S H Lim; S H Hyun; H S Kim; J Y Lee; K H Yoo; K S Jung; H-N Song; J Cho; S Park; Y H Ko; S J Kim; J Y Choi; W S Kim
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

3.  CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors:  Craig S Sauter; Brigitte Senechal; Isabelle Rivière; Ai Ni; Yvette Bernal; Xiuyan Wang; Terence Purdon; Malloury Hall; Ashvin N Singh; Victoria Z Szenes; Sarah Yoo; Ahmet Dogan; Yongzeng Wang; Craig H Moskowitz; Sergio Giralt; Matthew J Matasar; Miguel-Angel Perales; Kevin J Curran; Jae Park; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2019-07-01       Impact factor: 22.113

Review 4.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Victor A Chow; Mazyar Shadman; Ajay K Gopal
Journal:  Blood       Date:  2018-06-18       Impact factor: 22.113

6.  Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.

Authors:  Neha Mehta-Shah; Kimiteru Ito; Kurt Bantilan; Alison J Moskowitz; Craig Sauter; Steven M Horwitz; Heiko Schöder
Journal:  Blood Adv       Date:  2019-01-22

7.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Authors:  Partow Kebriaei; Harjeet Singh; M Helen Huls; Matthew J Figliola; Roland Bassett; Simon Olivares; Bipulendu Jena; Margaret J Dawson; Pappanaicken R Kumaresan; Shihuang Su; Sourindra Maiti; Jianliang Dai; Branden Moriarity; Marie-Andrée Forget; Vladimir Senyukov; Aaron Orozco; Tingting Liu; Jessica McCarty; Rineka N Jackson; Judy S Moyes; Gabriela Rondon; Muzaffar Qazilbash; Stefan Ciurea; Amin Alousi; Yago Nieto; Katy Rezvani; David Marin; Uday Popat; Chitra Hosing; Elizabeth J Shpall; Hagop Kantarjian; Michael Keating; William Wierda; Kim Anh Do; David A Largaespada; Dean A Lee; Perry B Hackett; Richard E Champlin; Laurence J N Cooper
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

8.  A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score.

Authors:  Ho-Young Yhim; Yael Eshet; Ur Metser; Chae-Hong Lim; Katherine Lajkosz; Keren Isaev; Matthew Cooper; Anca Prica; Vishal Kukreti; Sita Bhella; Noémie Lang; Kyung-Han Lee; Wei Xu; David Hodgson; Richard Tsang; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim; Michael Crump; John Kuruvilla; Robert Kridel
Journal:  Blood Adv       Date:  2020-11-24

Review 9.  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Anupama Doraiswamy; Mansi R Shah; Rajat Bannerji
Journal:  Curr Hematol Malig Rep       Date:  2021-02-22       Impact factor: 3.952

10.  Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

Authors:  Nirav N Shah; Kwang W Ahn; Carlos Litovich; Yizeng He; Craig Sauter; Timothy S Fenske; Mehdi Hamadani
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.